Serostim Bio-identical Hgh Injections

Hormone Replacement Therapy

SEROSTIM

Serostim Approved by the Food and Drug Administration as a Treatment for HIV-Related Cachexia

Serostim is the only Human Growth Hormone Medical Treatment approved by the FDA for treating muscle wasting associated with the HIV Virus. Serostim has been shown to increase muscle mass and stabilize and increase healthy weight while reducing fatigue and endurance for physical activity.

Serostim History

Seventeen years ago, Serostim was fast-tracked for approval by the Food and Drug Administration. Any drugs which offer new and unique treatment options for patients with a severe and critical ailment can qualify for this streamlined version of the FDA-Approval Process. After being placed on this approval track, Serono (the creator of Serostim Bio-Identical HGH) began a large-scale study to fully evaluate the usefulness and safety profile of Serostim HGH for HIV-Wasting.

This medical trial was double-blind in nature and controlled by a placebo. In addition to this, the large-scale trial also involved numerous independent medical facilities. The results of this trial corroborated with initial small-scale trials, which hinted at the beneficial use of Serostim for this purpose.

FDA-Facilitated HGH Research showed that Serostim could stimulate the production of lean muscle and significantly reduce fatigue in patients suffering from HIV-Related Wasting. In addition to quantitative benefits related to Serostim HGH, patients also felt that the benefits provided by Serostim were significantly qualitatively beneficial.

Muscle Atrophy Among Worst Symptoms of HIV and AIDS

Lean muscle wasting is one of the most detrimental symptoms of HIV, and Serostim has been proven to alleviate or reverse the effects of this devastating condition. Stronger muscles and decreased fatigue give the body more resources to fight off other symptoms associated with the HIV Virus, increasing overall health outcomes for those that suffer from HIV.

Although Antiretroviral medications can alleviate many of the debilitating symptoms of the HIV Virus, it is clear that Serostim provides an additional benefit that Antiretroviral Drugs alone cannot produce alone. Combining these HIV Drugs with Serostim allows patients to live healthier lives closer to normal.

Pitfalls of Cachexia Due to HIV

HIV-Related Wasting Disease is a disorder that becomes progressively worse over time without treatment. The adverse effects of lean muscle atrophy degrade the human body and rapidly increase mortality rates over time without treatment. HIV Wasting is a Metabolism Disease that leads the body to burn organs and muscle tissue for energy.

This process is a physiological response to harmful stimuli associated with the HIV-Virus.

Even though the human body still has stores of usable fat, the HIV Virus tricks the body into burning vital muscle tissue rather than fat tissue. Because of this, patients suffering from HIV-Related Cachexia have a viciously imbalanced body-fat percentage, as the body burns structural muscle rather than emergency fat.

Lean muscle is a blanket term that refers to a number of types of tissue throughout the body, including organ tissue, the muscles themselves, and blood cells within the cardiovascular system.

Decreased Lean Muscle Mass vastly increases the risk of extreme physiological exhaustion, illness, and infection, which can overwhelm the weakened immune system of an HIV patient and vastly decrease their life quality and their long-term odds of survival. Serostim was designated as an Orphan Drug Treatment for HIV-Related Muscle Wasting by the Food and Drug Administration in 1991.

HGH-AIDS Study Protocol

The final seal approval for Serostim Human Growth Hormone Replacement Therapy was granted as a result of a dose-variable, double-blind, randomized large-scale medical study funded directly to assess the benefits of Serostim HGH Treatments. This clinical trial included 757 participants who all suffered from Wasting due to HIV or AIDS.

Subjects were not limited to the United States; international medical facilities and patients also participated. Patients were either provided Serostim Growth Hormone Injections daily or were provided injections daily, half of which were Serostim, half of which were placebo. A third group was injected with a placebo daily and served as the control.

HGH-AIDS Research Results

All groups received injections for an identical period and were then physiologically assessed at the end of an initial treatment period. Researchers found that patients receiving daily HGH Injections had significantly increased levels of lean muscle compared to the other subset of patients who only received a half dose.

Both of these groups of patients benefited significantly compared to a third group that simply received placebo injections. In both experimental groups, patients could perceive the benefits of Serostim Subcutaneous Injections in their everyday life.

All patients who completed the first three months of the controlled clinical trial maintained treatment beyond the initial phase of a clinical study. Of the 646 patients that completed the initial study, 548 remained in treatment for an extra three months. Among all of these patients, the benefits of Serostim on muscle mass maintenance continued to accrue.

Currently, Serostim Recombinant HGH Therapy is the only HGH Treatment approved by the Food and Drug Administration for treating HIV-Related Cachexia. The dose recommended by the FDA is 0.1 Milligram per Kilogram each day.

For patients that weigh more than fifty-five kilograms, the maximum dose is six milligrams of Serostim per day. Patients at increased risk of side effects should be prescribed half of a standard weekly dose provided every other day.

HGH Caused Relatively Few Side-Effects

For the most part, Serostim produces very few side effects. The most reported side-effects of treatment were edema and non-severe joint and muscle pain. Any side effects are directly related to the size of the dose, and side effects eventually subsided either as treatment continued or with a reduction in dose size.

In a tiny minority of patients, issues related to glucose tolerance occurred, including the exacerbation of insulin sensitivity or the uncovering of underlying Type-Two Diabetes. In some of these latter patients, Insulin treatments had to be initiated or adjusted as a result of treatment. Patients with HIV-Wasting Disease with a history of Diabetes or insulin sensitivity should be closely monitored during HGH Treatment.

HGH High-Dosage AIDS Treatment

It should be noted that the Human Growth Hormone Dosage used to treat HIV-Related Cachexia is significantly higher than that used to treat Adult-Onset Human Growth Hormone Deficiency therapeutically.

Generally, the dose used to treat HGH Deficiency is between one and two IU per day, which is far less than the six milligrams per day generally prescribed to patients with severe Cachexia.

Human Growth Hormone has a remarkable capacity to stimulate the maintenance and development of lean muscle tissue in at-risk patients. In the future, there is no doubt that Human Growth Hormone Replacement Therapy will be highly beneficial for many other medical disorders.

Word Count: 1100